Journal of Oncology Translational Research

ISSN: 2476-2261

Open Access

Edward S Kim


  • Review Article
    Choosing the Best EGFR TKI in the Era of Precision Medicine
    Author(s): Zachary L Farmer, Kathryn F Mileham and Edward S KimZachary L Farmer, Kathryn F Mileham and Edward S Kim

    The treatment of metastatic Non-small Cell Lung Cancer (mNSCLC) has evolved from traditional doublet chemotherapy to a model for precision medicine. Over the past fifteen years, the discovery of Epidermal Growth Factor Receptor (EGFR) mutations as key players in the pathogenesis of mNSCLC has transformed the care of patients with mNSCLC. EGFR Tyrosine Kinase Inhibitors (TKIs) have prolonged both progression free survival and overall survival in patients who harbor EGFR mutations. Most recently, the third generation EGFR TKI osimertinib has shown superior progression free survival compared to earlier TKIs. Osimertinib has also shown excellent penetration into the CNS, less CNS tumor progression, and even leptomeningeal disease response. The efficacy of EGFR TKIs in the CNS may allow clinicians to avoid or defer radiation therapy for CNS disease in select mNSCLC patients with EGFR mutat.. Read More»
    DOI: 10.4172/2476-2261.1000133

    Abstract PDF

Relevant Topics

arrow_upward arrow_upward